MyoKardia (MYOK):

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of MyoKardia (NASDAQ: MYOK) after a clinical update on 1Q17 call, where management announced an uneventful interim safety analysis and expansion of the Phase 2 PIONEER HCM trial of MYK-461 to include patients on beta blockers.

The analyst believes the addition of a beta blocker cohort should de-risk the EXPLORER-HCM trial given widespread off label use in HCM patients. He expects PIONEER HCM to help establish correlation between reduction in LVOT and functional endpoints such as increase in peak VO2 (primary endpoint in Phase 3).

No change to the price target of $32.

For an analyst ratings summary and ratings history on MyoKardia click here. For more ratings news on MyoKardia click here.

Shares of MyoKardia closed at $13.15 yesterday.

You May Also Be Interested In